Axa’s Takeda Pharmaceutical TAK Stock Holding History

Axa’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,862	Closed	-$44.2K	–	910
2025 Q2	$44.2K	Hold	2,862	–	–	﹤0.01%	1113
2025 Q1	$42.6K	Hold	2,862	–	–	﹤0.01%	1048
2024 Q4	$37.9K	Hold	2,862	–	–	﹤0.01%	1059
2024 Q3	$40.7K	Sell	2,862 -708	-20%	-$10K	﹤0.01%	1079
2024 Q2	$46.2K	Hold	3,570	–	–	﹤0.01%	1049
2024 Q1	$49.6K	Buy	3,570 +695	+24%	+$10.1K	﹤0.01%	1050
2023 Q4	$41K	Buy	2,875 +640	+29%	+$9.08K	﹤0.01%	1052
2023 Q3	$34.6K	Hold	2,235	–	–	﹤0.01%	1052
2023 Q2	$35.1K	Hold	2,235	–	–	﹤0.01%	1071
2023 Q1	$36.8K	Buy	2,235 +22	+1%	+$350	﹤0.01%	1093
2022 Q4	$34.5K	Sell	2,213 -344	-13%	-$4.8K	﹤0.01%	1123
2022 Q3	$33.2K	Buy	+2,557	New	+$35.6K	﹤0.01%	1119
2021 Q1	–	Sell	-2,375	Closed	-$43K	–	1330
2020 Q4	$43K	Buy	2,375 +263	+12%	+$4.61K	﹤0.01%	1219
2020 Q3	$38K	Buy	+2,112	New	+$38.5K	﹤0.01%	1228

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Axa's TAK Position: Q3 2025 in Review

Axa sold out of Takeda Pharmaceutical (TAK) in Q3 2025, closing a stake of 2,862 shares — an estimated $44.2K sold.

Axa first reported a position in TAK in Q3 2020 and held it in 14 quarters. The position peaked at $49.6K in Q1 2024. 329 funds tracked by Wall St. Rank hold TAK as of Q3 2025.

Axa reported no remaining Takeda Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Axa sold 2,862 Takeda Pharmaceutical shares in Q3 2025, an estimated $44.2K.
Axa first reported a position in Takeda Pharmaceutical in Q3 2020 and held it in 14 quarters.
Axa's Takeda Pharmaceutical position peaked at $49.6K in Q1 2024.
329 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.